 <h1>Stimate Side Effects</h1><p class="drug-subtitle"><b>Generic Name:</b> <i>desmopressin</i></p><ul class="ddc-anchor-links"><li>Consumer</li>
<li>Professional</li>
<li>FAQ</li></ul><p class="ddc-notification"><b>Note:</b> This document contains side effect information about desmopressin. Some of the dosage forms listed on this page <em>may not</em> apply to the brand name Stimate.</p><h2 class="ddc-anchor-offset" id="consumer">For the Consumer</h2><p><i>Applies to desmopressin: oral tablet</i></p><p>Other dosage forms:</p><ul><li>sublingual tablet</li><li>injection solution</li><li>nasal solution, nasal spray</li></ul><h3>Side effects requiring immediate medical attention</h3><p>Along with its needed effects, desmopressin (the active ingredient contained in Stimate) may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.</p><p>
<b>Check with your doctor immediately</b> if any of the following side effects occur while taking desmopressin:</p><p>
<i>Rare</i>
</p><ul>
<li>Confusion</li>
<li>convulsions</li>
<li>decreased urine output</li>
<li>dizziness</li>
<li>fast or irregular heartbeat</li>
<li>headache</li>
<li>increased thirst</li>
<li>muscle pain or cramps</li>
<li>nausea or vomiting</li>
<li>shortness of breath</li>
<li>swelling of the face, ankles, or hands</li>
<li>unusual tiredness or weakness</li>
</ul><p>
<i>Incidence not known</i>
</p><ul>
<li>Weight gain</li>
</ul><h3>Side effects not requiring immediate medical attention</h3><p>Some side effects of desmopressin may occur that usually <b>do not need medical attention</b>. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects.</p><p>Check with your health care professional if any of the following side effects <b>continue or are bothersome</b> or if you have any questions about them:</p><p>
<i>Incidence not known</i>
</p><ul>
<li>Delusions</li>
<li>dementia</li>
<li>diarrhea</li>
</ul><p>
<div class="related-links"><svg aria-hidden="true" class="ddc-icon ddc-icon-info" focusable="false" height="22" viewbox="0 0 24 24" width="22" xmlns="http://www.w3.org/2000/svg"><path d="M14 2H6c-1.1 0-1.99.9-1.99 2L4 20c0 1.1.89 2 1.99 2H18c1.1 0 2-.9 2-2V8l-6-6zm2 16H8v-2h8v2zm0-4H8v-2h8v2zm-3-5V3.5L18.5 9H13z"></path></svg> <span>Managing side effects <span class="ddc-text-nowrap">(general information)</span></span></div>
<h2 class="ddc-anchor-offset" id="professional">For Healthcare Professionals</h2><p><i>Applies to desmopressin: injectable solution, nasal solution, nasal spray, oral tablet, sublingual tablet</i></p><h3>Cardiovascular</h3><p>One review of the literature found that the incidence of thrombotic events associated with the use of DDAVP to reduce blood loss and transfusion requirements in surgical patients was not significantly higher than placebo.  In any case, the incidence of thrombosis is rare.  One review found only 10 reports of thrombosis over a 4-year period, covering 433,000 doses of DDAVP.<sup>[Ref]</sup></p><p>Cardiovascular side effects have infrequently included transient and slight elevations or reductions in blood pressure, a compensatory change in heart rate, and facial flushing with injections of desmopressin (DDAVP).  Vasodilation and water retention have occurred.  There have been rare reports of thrombotic events (acute cerebral thrombosis, acute myocardial infarction) in some patients after DDAVP injection.  At least one case of fatal left coronary thrombosis has been associated with the use of DDAVP.<sup>[Ref]</sup></p><h3>Nervous system</h3><p>Nervous system side effects have included seizures and/or coma as a result of severe water intoxication and hyponatremia.  Other nervous system side effects have included headache and dizziness in less than 3% of patients.  DDAVP nasal spray has been infrequently associated with somnolence, lethargy, paresthesias, fatigue, confusion, stupor, malaise, diaphoresis, itchy or light-sensitive eyes, insomnia, chills, warm feeling, and agitation.<sup>[Ref]</sup></p><p>The risk factors for DDAVP-induced hyponatremia include stress, surgery, anesthesia, narcotics (endogenous release of ADH), vomiting (loss of sodium), liver disease (hindered metabolism of DDAVP), overhydration with hyponatremic fluids, and advanced age.  In some cases, fluid restriction, avoidance of hyponatremic solutions, and close monitoring of serum electrolytes and urine output for at least 15 to 20 hours after the administration of DDAVP may be beneficial.<sup>[Ref]</sup></p><h3>Hematologic</h3><p>Hematologic side effects have included platelet aggregation and thrombocytopenia.  These have been seen almost uniquely in patients with von Willebrand's disease Type IIB (DDAVP is contraindicated in these patients).<sup>[Ref]</sup></p><h3>Local</h3><p>Local side effects of injections of DDAVP have included intravenous site erythema, swelling, and burning.<sup>[Ref]</sup></p><h3>Respiratory</h3><p>Respiratory side effects of intranasal DDAVP have included rhinitis, epistaxis, and nostril pain in 2% to 10% of patients.  Apnea and cardiac arrest occurred in one patient.<sup>[Ref]</sup></p><h3>Gastrointestinal</h3><p>Gastrointestinal side effects have included mild abdominal cramps and nausea in 2% of patients.  Dyspepsia and vomiting have rarely been associated with DDAVP nasal spray.<sup>[Ref]</sup></p><h3>Hypersensitivity</h3><p>Hypersensitivity reactions have rarely included anaphylaxis.<sup>[Ref]</sup></p><h3>Psychiatric</h3><p>Psychiatric side effects have included a single case of paranoid psychosis associated with the use of DDAVP nasal spray.<sup>[Ref]</sup></p><div class="referenceList"><h4 id="refs">References</h4><p id="ref_1">1. Pigache RM "Facial flushing induced by vasopressin-like peptides lacking pressor activity." Br J Clin Pharmacol 17 (1984): 369-71</p><p id="ref_2">2. "Product Information. DDAVP (desmopressin)." Rhone-Poulenc Rorer, Collegeville, PA. </p><p id="ref_3">3. Mannucci PM, Carlsson S, Harris AS "Desmopressin, surgery and thrombosis." Thromb Haemost 71 (1994): 154-5</p><p id="ref_4">4. Bond L, Bevan D "Myocardial infarction in a patient with hemophilia treated with DDAVP." N Engl J Med 318 (1988): 121</p><p id="ref_5">5. Brommer EJ, van Brummelen P, Derkx FH "Desmopressin and hypotension." Ann Intern Med 103 (1985): 962</p><p id="ref_6">6. Vermylen J, Peerlinck K "Fatal complication of desmopressin." Lancet 346 (1995): 447</p><p id="ref_7">7. Lowe GD "Desmopressin and myocardial infarction." Lancet 1 (1989): 895-6</p><p id="ref_8">8. Salva KM, Kim HC, Nahum K, Fallot PL "DDAVP in the treatment of bleeding disorders." Pharmacotherapy 8 (1988): 94-9</p><p id="ref_9">9. D'Alauro FS, Johns RA "Hypotension related to desmopressin administration following cardiopulmonary bypass." Anesthesiology 69 (1988): 962-3</p><p id="ref_10">10. "Product Information. Stimate (desmopressin)." Forest Pharmaceuticals, St. Louis, MO. </p><p id="ref_11">11. Israels SJ, Kobrinsky NL "Serious reaction to desmopressin in a child with cyanotic heart disease." N Engl J Med 320 (1989): 1563-4</p><p id="ref_12">12. Vigano GL, Mannucci PM, Lattuada A, Harris A, Remuzzi G "Subcutaneous desmopressin (DDAVP) shortens the bleeding time in uremia." Am J Hematol 31 (1989): 32-5</p><p id="ref_13">13. Hjalmas K, Bengtsson B "Efficacy, safety, and dosing of desmopressin for nocturnal enuresis in Europe." Clin Pediatr (Phila) Spec No (1993): 19-24</p><p id="ref_14">14. Miller K, Atkin B, Moody ML "Drug therapy for nocturnal enuresis. Current treatment recommendations." Drugs 44 (1992): 47-56</p><p id="ref_15">15. Hartmann S "Fatal complication of desmopressin - reply." Lancet 346 (1995): 447</p><p id="ref_16">16. Byrnes JJ, Larcada A, Moake JL "Thrombosis following desmopressin for uremic bleeding." Am J Hematol 28 (1988): 63-5</p><p id="ref_17">17. Mannucci PM, Lusher JM "Desmopressin and thrombosis." Lancet 2 (1989): 675-6</p><p id="ref_18">18. Hartmann S, Reinhart W "Fatal complication of desmopressin." Lancet 345 (1995): 1302-3</p><p id="ref_19">19. Albert SG, Salvato-Lechner V, Joist JH "Venous thromboembolism and transient thrombocytopenia in a patient with diabetes insipidus treated with desmopressin acetate (DDAVP)." Thromb Res 50 (1988): 695-705</p><p id="ref_20">20. Sun HL, Chien CC "Thrombocytopenia and subdural hemorrhage after desmopressin administration." Anesthesiology 88 (1998): 1115-7</p><p id="ref_21">21. Shulman LH, Miller JL, Rose LI "Desmopressin for diabetes insipidus, hemostatic disorders and enuresis." Am Fam Physician 42 (1990): 1051-7</p><p id="ref_22">22. McLeod BC "Myocardial infarction in a blood donor after administration of desmopressin." Lancet 336 (1990): 1137-8</p><p id="ref_23">23. Harris AS "Clinical experience with desmopressin: efficacy and safety in central diabetes insipidus and other conditions." J Pediatr 114 (1989): 711-8</p><p id="ref_24">24. Asplund R, Aberg H "Desmopressin in elderly women with increased nocturnal diuresis. A short-term study." Br J Urol 72 (1993): 42-5</p><p id="ref_25">25. Odeh M, Oliven A "Coma and seizures due to severe hyponatremia and water intoxication in an adult with intranasal desmopressin therapy for nocturnal enuresis." J Clin Pharmacol 41 (2001): 582-4</p><p id="ref_26">26. Sukhai RN "Enuresis nocturna: long term use and safety aspects of minrin (desmopressin) spray." Regul Pept 45 (1993): 309-10</p><p id="ref_27">27. Kallio J, Rautava P, Huupponen R, Korvenranta H "Severe hyponatremia caused by intranasal desmopressin for nocturnal enuresis." Acta Paediatr 82 (1993): 881-2</p><p id="ref_28">28. Shepherd LL, Hutchinson RJ, Worden EK, Koopmann CF, Coran A "Hyponatremia and seizures after intravenous administration of desmopressin acetate for surgical hemostasis." J Pediatr 114 (1989): 470-2</p><p id="ref_29">29. Schwab M, Wenzel D, Ruder H "Hyponatraemia and cerebral convulsion due to short term DDAVP therapy for control of enuresis nocturna." Eur J Pediatr 155 (1996): 46-8</p><p id="ref_30">30. Williford SL "Water intoxication in patients treated with desmopressin - reply." Pharmacotherapy 16 (1996): 970</p><p id="ref_31">31. Hamed M, Mitchell H, Clow DJ "Hyponatraemic convulsion associated with desmopressin and imipramine treatment." BMJ 306 (1993): 1169</p><p id="ref_32">32. Simmonds EJ, Mahony MJ, Little JM "Convulsion and coma after intranasal desmopressin in cystic fibrosis." BMJ 297 (1988): 1614</p><p id="ref_33">33. Robson WLM "Water intoxication in patients treated with desmopressin." Pharmacotherapy 16 (1996): 969-70</p><p id="ref_34">34. Williford SL, Bernstein SA "Intranasal desmopressin-induced hyponatremia." Pharmacotherapy 16 (1996): 66-74</p><p id="ref_35">35. Smith TJ, Gill JC, Ambruso DR, Hathaway WE "Hyponatremia and seizures in young children given DDAVP." Am J Hematol 31 (1989): 199-202</p><p id="ref_36">36. Yaouyanc G, Jonville AP, Yaouyanc-Lapalle H, Barbier P, Dutertre JP, Autret E "Seizure with hyponatremia in a child prescribed desmopressin for nocturnal enuresis." J Toxicol Clin Toxicol 30 (1992): 637-41</p><p id="ref_37">37. Weinstein RE, Bona RD, Altman AJ, Quinn JJ, Weisman SJ, Bartolomeo A, Rickles FR "Severe hyponatremia after repeated intravenous administration of desmopressin." Am J Hematol 32 (1989): 258-61</p><p id="ref_38">38. Humphries JE, Siragy H "Significant hyponatremia following DDAVP administration in a healthy adult." Am J Hematol 44 (1993): 12-5</p><p id="ref_39">39. Hourihane J, Salisbury AJ "Use caution in prescribing desmopressin for nocturnal enuresis." BMJ 306 (1993): 1545</p><p id="ref_40">40. Robson WLM, Norgaard JP, Leung AKC "Hyponatremia in patients with nocturnal enuresis treated with DDAVP." Eur J Pediatr 155 (1996): 959-62</p><p id="ref_41">41. Stenberg A, Lackgren G "Desmopressin tablets in the treatment of severe nocturnal enuresis in adolescents." Pediatrics 94 (1994): 841-6</p><p id="ref_42">42. Beach PS, Beach RE, Smith LR "Hyponatremic seizures in a child treated with desmopressin to control enuresis. A rational approach to fluid intake." Clin Pediatr (Phila) 31 (1992): 566-9</p><p id="ref_43">43. Sweeney JD, Hoernig LA, Behrens AN, Novak E, Swank RT "von Willebrand's variant (type II Buffalo). Thrombocytopenia after desmopressin but absence of in vitro hypersensitivity to ristocetin." Am J Clin Pathol 93 (1990): 522-5</p><p id="ref_44">44. Castaman G, Rodeghiero F, Lattuada A, Mannucci PM "Desmopressin-induced thrombocytopenia in type I platelet discordant von Willebrand disease." Am J Hematol 43 (1993): 5-9</p><p id="ref_45">45. Holmberg L, Nilsson IM, Borge L, Gunnarsson M, Sjorin E "Platelet aggregation induced by 1-desamino-8-D-arginine vasopressin (DDAVP) in Type IIB von Willebrand's disease." N Engl J Med 309 (1983): 816-21</p><p id="ref_46">46. Itabashi A, Katayama S, Yamaji T "Hypersensitivity to chlorobutanol in DDAVP solution." Lancet 1 (1982): 108</p><p id="ref_47">47. Collins GB, Marzewski DJ, Rollins MB "Paranoid psychosis after DDAVP therapy for Alzheimer's dementia." Lancet 2 (1981): 808</p></div>
<h2 class="ddc-anchor-offset" id="faq">Frequently asked questions</h2>
<ul>
<li>What is the difference in Nocdurna dosage between men and women?</li>
<li>How does Noctiva work?</li>
</ul>
<div class="more-resources" id="moreResources">
<h2>More about Stimate (desmopressin)</h2>
<ul class="more-resources-list more-resources-list-general">
<li>During Pregnancy or 
Breastfeeding</li>
<li>Dosage Information</li>
<li>Drug Interactions</li>
<li>Compare Alternatives</li>
<li>Pricing &amp; Coupons</li>
<li>En Español</li>
<li>3 Reviews</li>
<li>Drug class: antidiuretic hormones</li>
<li>FDA Alerts (2)</li>
</ul>
<h3>Consumer resources</h3>
<ul class="more-resources-list more-resources-list-consumer">
<li>Patient Information</li>
<li>Stimate &lt;span&gt;(Advanced Reading)&lt;/span&gt;</li>
</ul>
<dl class="more-resources-other-brands more-resources-other-brands-consumer"><dt>Other brands</dt><dd>DDAVP, Minirin, Nocdurna, Noctiva, DDAVP Rhinal Tube</dd></dl>
<h3>Professional resources</h3>
<ul class="more-resources-list more-resources-list-professional">
<li>Prescribing Information</li>
<li data-more-config-id="list-data-resources-professional">... +1 more</li>
</ul>
<h3>Related treatment guides</h3>
<ul class="more-resources-list more-resources-list-conditions">
<li>Hemophilia A</li>
<li>von Willebrand Disease</li>
</ul>
</div>
<h2>Further information</h2><p class="ddc-disclaimer">Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.</p>
<p>Some side effects may not be reported. You may report them to the FDA.</p>
<p class="ddc-disclaimer-link">Medical Disclaimer</p>
<script>
function showRefs(refs) {
	if (!document.querySelectorAll) {
		return;
	}

	var referenceIds = refs ? refs.split(',') : [];
	var referenceTitle = referenceIds.length
		 ? "References relevant to chosen section <span class='ddc-text-size-small font-weight-normal'>(<a href='#refs' onclick='showRefs(\"\"); return false;'>Show all references</a>)</span>"
		 : "References";
	document.getElementById('refs').innerHTML = referenceTitle;

	// Show/hide reference items
	var referenceList = document.querySelectorAll('.referenceList p');
	referenceList.forEach(function(item) {
		var id = item.id.replace('ref_', '');
		if (!referenceIds.length || referenceIds.includes(id)) {
			item.style.display = 'block';
		}
		else {
			item.style.display = 'none';
		}
	});
}
</script>
</p><h2 class="ddc-anchor-offset" id="professional">For Healthcare Professionals</h2><p><i>Applies to desmopressin: injectable solution, nasal solution, nasal spray, oral tablet, sublingual tablet</i></p><h3>Cardiovascular</h3><p>One review of the literature found that the incidence of thrombotic events associated with the use of DDAVP to reduce blood loss and transfusion requirements in surgical patients was not significantly higher than placebo.  In any case, the incidence of thrombosis is rare.  One review found only 10 reports of thrombosis over a 4-year period, covering 433,000 doses of DDAVP.<sup>[Ref]</sup></p><p>Cardiovascular side effects have infrequently included transient and slight elevations or reductions in blood pressure, a compensatory change in heart rate, and facial flushing with injections of desmopressin (DDAVP).  Vasodilation and water retention have occurred.  There have been rare reports of thrombotic events (acute cerebral thrombosis, acute myocardial infarction) in some patients after DDAVP injection.  At least one case of fatal left coronary thrombosis has been associated with the use of DDAVP.<sup>[Ref]</sup></p><h3>Nervous system</h3><p>Nervous system side effects have included seizures and/or coma as a result of severe water intoxication and hyponatremia.  Other nervous system side effects have included headache and dizziness in less than 3% of patients.  DDAVP nasal spray has been infrequently associated with somnolence, lethargy, paresthesias, fatigue, confusion, stupor, malaise, diaphoresis, itchy or light-sensitive eyes, insomnia, chills, warm feeling, and agitation.<sup>[Ref]</sup></p><p>The risk factors for DDAVP-induced hyponatremia include stress, surgery, anesthesia, narcotics (endogenous release of ADH), vomiting (loss of sodium), liver disease (hindered metabolism of DDAVP), overhydration with hyponatremic fluids, and advanced age.  In some cases, fluid restriction, avoidance of hyponatremic solutions, and close monitoring of serum electrolytes and urine output for at least 15 to 20 hours after the administration of DDAVP may be beneficial.<sup>[Ref]</sup></p><h3>Hematologic</h3><p>Hematologic side effects have included platelet aggregation and thrombocytopenia.  These have been seen almost uniquely in patients with von Willebrand's disease Type IIB (DDAVP is contraindicated in these patients).<sup>[Ref]</sup></p><h3>Local</h3><p>Local side effects of injections of DDAVP have included intravenous site erythema, swelling, and burning.<sup>[Ref]</sup></p><h3>Respiratory</h3><p>Respiratory side effects of intranasal DDAVP have included rhinitis, epistaxis, and nostril pain in 2% to 10% of patients.  Apnea and cardiac arrest occurred in one patient.<sup>[Ref]</sup></p><h3>Gastrointestinal</h3><p>Gastrointestinal side effects have included mild abdominal cramps and nausea in 2% of patients.  Dyspepsia and vomiting have rarely been associated with DDAVP nasal spray.<sup>[Ref]</sup></p><h3>Hypersensitivity</h3><p>Hypersensitivity reactions have rarely included anaphylaxis.<sup>[Ref]</sup></p><h3>Psychiatric</h3><p>Psychiatric side effects have included a single case of paranoid psychosis associated with the use of DDAVP nasal spray.<sup>[Ref]</sup></p><p id="ref_1">1. Pigache RM "Facial flushing induced by vasopressin-like peptides lacking pressor activity." Br J Clin Pharmacol 17 (1984): 369-71</p><p id="ref_2">2. "Product Information. DDAVP (desmopressin)." Rhone-Poulenc Rorer, Collegeville, PA. </p><p id="ref_3">3. Mannucci PM, Carlsson S, Harris AS "Desmopressin, surgery and thrombosis." Thromb Haemost 71 (1994): 154-5</p><p id="ref_4">4. Bond L, Bevan D "Myocardial infarction in a patient with hemophilia treated with DDAVP." N Engl J Med 318 (1988): 121</p><p id="ref_5">5. Brommer EJ, van Brummelen P, Derkx FH "Desmopressin and hypotension." Ann Intern Med 103 (1985): 962</p><p id="ref_6">6. Vermylen J, Peerlinck K "Fatal complication of desmopressin." Lancet 346 (1995): 447</p><p id="ref_7">7. Lowe GD "Desmopressin and myocardial infarction." Lancet 1 (1989): 895-6</p><p id="ref_8">8. Salva KM, Kim HC, Nahum K, Fallot PL "DDAVP in the treatment of bleeding disorders." Pharmacotherapy 8 (1988): 94-9</p><p id="ref_9">9. D'Alauro FS, Johns RA "Hypotension related to desmopressin administration following cardiopulmonary bypass." Anesthesiology 69 (1988): 962-3</p><p id="ref_10">10. "Product Information. Stimate (desmopressin)." Forest Pharmaceuticals, St. Louis, MO. </p><p id="ref_11">11. Israels SJ, Kobrinsky NL "Serious reaction to desmopressin in a child with cyanotic heart disease." N Engl J Med 320 (1989): 1563-4</p><p id="ref_12">12. Vigano GL, Mannucci PM, Lattuada A, Harris A, Remuzzi G "Subcutaneous desmopressin (DDAVP) shortens the bleeding time in uremia." Am J Hematol 31 (1989): 32-5</p><p id="ref_13">13. Hjalmas K, Bengtsson B "Efficacy, safety, and dosing of desmopressin for nocturnal enuresis in Europe." Clin Pediatr (Phila) Spec No (1993): 19-24</p><p id="ref_14">14. Miller K, Atkin B, Moody ML "Drug therapy for nocturnal enuresis. Current treatment recommendations." Drugs 44 (1992): 47-56</p><p id="ref_15">15. Hartmann S "Fatal complication of desmopressin - reply." Lancet 346 (1995): 447</p><p id="ref_16">16. Byrnes JJ, Larcada A, Moake JL "Thrombosis following desmopressin for uremic bleeding." Am J Hematol 28 (1988): 63-5</p><p id="ref_17">17. Mannucci PM, Lusher JM "Desmopressin and thrombosis." Lancet 2 (1989): 675-6</p><p id="ref_18">18. Hartmann S, Reinhart W "Fatal complication of desmopressin." Lancet 345 (1995): 1302-3</p><p id="ref_19">19. Albert SG, Salvato-Lechner V, Joist JH "Venous thromboembolism and transient thrombocytopenia in a patient with diabetes insipidus treated with desmopressin acetate (DDAVP)." Thromb Res 50 (1988): 695-705</p><p id="ref_20">20. Sun HL, Chien CC "Thrombocytopenia and subdural hemorrhage after desmopressin administration." Anesthesiology 88 (1998): 1115-7</p><p id="ref_21">21. Shulman LH, Miller JL, Rose LI "Desmopressin for diabetes insipidus, hemostatic disorders and enuresis." Am Fam Physician 42 (1990): 1051-7</p><p id="ref_22">22. McLeod BC "Myocardial infarction in a blood donor after administration of desmopressin." Lancet 336 (1990): 1137-8</p><p id="ref_23">23. Harris AS "Clinical experience with desmopressin: efficacy and safety in central diabetes insipidus and other conditions." J Pediatr 114 (1989): 711-8</p><p id="ref_24">24. Asplund R, Aberg H "Desmopressin in elderly women with increased nocturnal diuresis. A short-term study." Br J Urol 72 (1993): 42-5</p><p id="ref_25">25. Odeh M, Oliven A "Coma and seizures due to severe hyponatremia and water intoxication in an adult with intranasal desmopressin therapy for nocturnal enuresis." J Clin Pharmacol 41 (2001): 582-4</p><p id="ref_26">26. Sukhai RN "Enuresis nocturna: long term use and safety aspects of minrin (desmopressin) spray." Regul Pept 45 (1993): 309-10</p><p id="ref_27">27. Kallio J, Rautava P, Huupponen R, Korvenranta H "Severe hyponatremia caused by intranasal desmopressin for nocturnal enuresis." Acta Paediatr 82 (1993): 881-2</p><p id="ref_28">28. Shepherd LL, Hutchinson RJ, Worden EK, Koopmann CF, Coran A "Hyponatremia and seizures after intravenous administration of desmopressin acetate for surgical hemostasis." J Pediatr 114 (1989): 470-2</p><p id="ref_29">29. Schwab M, Wenzel D, Ruder H "Hyponatraemia and cerebral convulsion due to short term DDAVP therapy for control of enuresis nocturna." Eur J Pediatr 155 (1996): 46-8</p><p id="ref_30">30. Williford SL "Water intoxication in patients treated with desmopressin - reply." Pharmacotherapy 16 (1996): 970</p><p id="ref_31">31. Hamed M, Mitchell H, Clow DJ "Hyponatraemic convulsion associated with desmopressin and imipramine treatment." BMJ 306 (1993): 1169</p><p id="ref_32">32. Simmonds EJ, Mahony MJ, Little JM "Convulsion and coma after intranasal desmopressin in cystic fibrosis." BMJ 297 (1988): 1614</p><p id="ref_33">33. Robson WLM "Water intoxication in patients treated with desmopressin." Pharmacotherapy 16 (1996): 969-70</p><p id="ref_34">34. Williford SL, Bernstein SA "Intranasal desmopressin-induced hyponatremia." Pharmacotherapy 16 (1996): 66-74</p><p id="ref_35">35. Smith TJ, Gill JC, Ambruso DR, Hathaway WE "Hyponatremia and seizures in young children given DDAVP." Am J Hematol 31 (1989): 199-202</p><p id="ref_36">36. Yaouyanc G, Jonville AP, Yaouyanc-Lapalle H, Barbier P, Dutertre JP, Autret E "Seizure with hyponatremia in a child prescribed desmopressin for nocturnal enuresis." J Toxicol Clin Toxicol 30 (1992): 637-41</p><p id="ref_37">37. Weinstein RE, Bona RD, Altman AJ, Quinn JJ, Weisman SJ, Bartolomeo A, Rickles FR "Severe hyponatremia after repeated intravenous administration of desmopressin." Am J Hematol 32 (1989): 258-61</p><p id="ref_38">38. Humphries JE, Siragy H "Significant hyponatremia following DDAVP administration in a healthy adult." Am J Hematol 44 (1993): 12-5</p><p id="ref_39">39. Hourihane J, Salisbury AJ "Use caution in prescribing desmopressin for nocturnal enuresis." BMJ 306 (1993): 1545</p><p id="ref_40">40. Robson WLM, Norgaard JP, Leung AKC "Hyponatremia in patients with nocturnal enuresis treated with DDAVP." Eur J Pediatr 155 (1996): 959-62</p><p id="ref_41">41. Stenberg A, Lackgren G "Desmopressin tablets in the treatment of severe nocturnal enuresis in adolescents." Pediatrics 94 (1994): 841-6</p><p id="ref_42">42. Beach PS, Beach RE, Smith LR "Hyponatremic seizures in a child treated with desmopressin to control enuresis. A rational approach to fluid intake." Clin Pediatr (Phila) 31 (1992): 566-9</p><p id="ref_43">43. Sweeney JD, Hoernig LA, Behrens AN, Novak E, Swank RT "von Willebrand's variant (type II Buffalo). Thrombocytopenia after desmopressin but absence of in vitro hypersensitivity to ristocetin." Am J Clin Pathol 93 (1990): 522-5</p><p id="ref_44">44. Castaman G, Rodeghiero F, Lattuada A, Mannucci PM "Desmopressin-induced thrombocytopenia in type I platelet discordant von Willebrand disease." Am J Hematol 43 (1993): 5-9</p><p id="ref_45">45. Holmberg L, Nilsson IM, Borge L, Gunnarsson M, Sjorin E "Platelet aggregation induced by 1-desamino-8-D-arginine vasopressin (DDAVP) in Type IIB von Willebrand's disease." N Engl J Med 309 (1983): 816-21</p><p id="ref_46">46. Itabashi A, Katayama S, Yamaji T "Hypersensitivity to chlorobutanol in DDAVP solution." Lancet 1 (1982): 108</p><p id="ref_47">47. Collins GB, Marzewski DJ, Rollins MB "Paranoid psychosis after DDAVP therapy for Alzheimer's dementia." Lancet 2 (1981): 808</p><h2 class="ddc-anchor-offset" id="faq">Frequently asked questions</h2><ul>
<li>What is the difference in Nocdurna dosage between men and women?</li>
<li>How does Noctiva work?</li>
</ul><h2>More about Stimate (desmopressin)</h2><ul class="more-resources-list more-resources-list-general">
<li>During Pregnancy or 
Breastfeeding</li>
<li>Dosage Information</li>
<li>Drug Interactions</li>
<li>Compare Alternatives</li>
<li>Pricing &amp; Coupons</li>
<li>En Español</li>
<li>3 Reviews</li>
<li>Drug class: antidiuretic hormones</li>
<li>FDA Alerts (2)</li>
</ul><h3>Consumer resources</h3><ul class="more-resources-list more-resources-list-consumer">
<li>Patient Information</li>
<li>Stimate &lt;span&gt;(Advanced Reading)&lt;/span&gt;</li>
</ul><h3>Professional resources</h3><ul class="more-resources-list more-resources-list-professional">
<li>Prescribing Information</li>
<li data-more-config-id="list-data-resources-professional">... +1 more</li>
</ul><h3>Related treatment guides</h3><ul class="more-resources-list more-resources-list-conditions">
<li>Hemophilia A</li>
<li>von Willebrand Disease</li>
</ul><h2>Further information</h2><p class="ddc-disclaimer">Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.</p><p>Some side effects may not be reported. You may report them to the FDA.</p><p class="ddc-disclaimer-link">Medical Disclaimer</p>